Welcome to our dedicated page for CODEXIS SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Codexis, Inc. filings document the company's public-company disclosures as a Nasdaq-listed biotechnology issuer focused on enzymatic solutions for therapeutics manufacturing. Recent 8-K reports furnish quarterly and annual operating results, financial-condition updates, business-update exhibits, and material event disclosures tied to organizational streamlining and the ECO Synthesis platform.
Proxy materials describe annual meeting voting, board classes and committee membership, director elections, executive compensation, and other governance matters. The filing record also identifies Codexis common stock, par value $0.0001 per share, trading under CDXS on the Nasdaq Global Select Market.
Codexis (CDXS) filed its Q3 2025 10‑Q, reporting revenue of $8.6 million and a net loss of $19.6 million (basic and diluted loss per share $0.22). Product revenue was $6.8 million and research and development revenue was $1.8 million. Product gross margin was 64%.
Cash and cash equivalents were $25.4 million with short‑term investments of $33.4 million, totaling $58.7 million as of September 30, 2025. Long‑term debt was $39.7 million, primarily the Innovatus term loan. Operating cash use was $39.5 million for the nine‑month period; financing inflows included $17.3 million of common stock sales under the Cantor at‑the‑market agreement.
Subsequent events: in October 2025, Codexis entered an enzyme supply assurance agreement with Merck that provides a one‑time $37.8 million payment expected in Q4 2025. On November 6, 2025, the company announced a workforce reduction of approximately 24%, with an estimated $3.5 million expense expected in Q4 2025. Shares outstanding were 90,324,383 as of November 3, 2025.
Codexis, Inc. announced organizational and leadership changes. The company is implementing a workforce reduction of approximately 24% to align with its focus on the ECO Synthesis platform. It expects to recognize about $3.5 million of related expenses in the fourth quarter of 2025, paid primarily in the same period, with the reduction substantially completed by January 2026.
The Board appointed Alison Moore, Ph.D., as President and Chief Executive Officer and as a Class III director, effective November 7, 2025. Her compensation includes a $650,000 base salary, a target annual bonus of 75% of salary, 85,000 RSUs vesting over three years, and 500,000 stock options vesting over four years. Stephen Dilly will continue as Chair of the Board with annual cash fees of $110,000. Kevin Norrett entered into a separation and consulting agreement and will provide transitional services through November 6, 2026, and will receive a bonus equal to 100% of his target bonus.
Codexis (CDXS) reported an insider transaction by its Chief Financial Officer, Georgia Erbez. On 10/13/2025, she sold 6,239 shares of common stock at $2.505 per share. The filing notes the sale was made solely to satisfy tax or other government withholding obligations tied to the vesting of Restricted Stock Units.
Following the transaction, Erbez beneficially owned 70,636 shares directly, which includes 33,333 RSUs. The transaction code was listed as S, indicating a sale.
Codexis (CDXS) filed a Form 4 reporting that Chief Technical Officer Alison Moore sold 6,239 shares of common stock on 10/13/2025 at $2.5051 per share. The filing states the sale was made solely to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units.
Following the transaction, Alison Moore beneficially owns 169,332 shares, which includes 33,333 restricted stock units. Ownership is reported as direct, and the filing was made by one reporting person.
Codexis, Inc. filed a Form S-8 to register an additional 8,000,000 shares of its common stock for issuance under the Codexis, Inc. 2019 Incentive Award Plan, following a stockholder-approved amendment to the plan on June 10, 2025. The filing states these additional shares are in addition to shares registered under prior Form S-8 filings (June 21, 2019 and August 3, 2023), which remain effective, and that the new registration is submitted under General Instruction E to register additional securities of the same class.
The Registration Statement incorporates by reference the company’s Annual Report for the fiscal year ended December 31, 2024 (filed February 27, 2025), Quarterly Reports for the quarters ended March 31, 2025 (filed May 14, 2025) and June 30, 2025 (filed August 13, 2025), and several Current Reports filed in 2025. The filing also describes the company’s indemnification provisions for officers and directors and lists exhibits including legal opinions and auditor consents.
Codexis, Inc. reported improved quarterly performance. Total revenue for the three months ended June 30, 2025 was $15.3 million, up from $8.0 million a year earlier, driven by $7.4 million of product sales and $7.9 million of research and development revenue that included a $4.7 million milestone/license recognition. Product gross margin expanded to 72% in the quarter from 45% a year ago, helping reduce the quarterly loss to $13.3 million ($0.16 per share) versus a $22.8 million loss in Q2 2024.
Liquidity and financing: cash and cash equivalents totaled $26.8 million and short-term investments were $39.6 million, for combined cash and short-term investments of $66.3 million, and working capital of $73.5 million. The company has a $40.0 million term loan facility with Innovatus (second $10.0 million tranche funded June 27, 2025) and total long-term debt reported at $39.4 million with an effective interest rate of 12.7% as of June 30, 2025. Operating cash used was $31.8 million for the six months ended June 30, 2025. Codexis continues investment in its ECO Synthesis platform and pharma biocatalysis business.
Codexis, Inc. filed a current report to disclose that it has announced its financial results for the quarter ended June 30, 2025. The company released these results through a press release dated August 13, 2025, which is furnished as Exhibit 99.1. This press release contains the detailed quarterly financial information. The exhibit is furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities offerings unless specifically referenced.
Aberdeen Group plc and its U.S. affiliate abrdn Inc. jointly filed a Schedule 13G reporting passive ownership of 4,200,950 Codexis (CDXS) common shares as of 30 Jun 2025. The position equals 5.07 % of outstanding stock, making the firms a 5-percent beneficial owner under SEC rules.
The filing states shared voting and dispositive power over the entire stake; neither entity holds sole authority. Aberdeen is classified as a parent holding company/control person (HC) incorporated in the United Kingdom, while abrdn Inc. is a U.S. corporation and registered investment adviser (CO, IA). Both certify the shares were acquired in the ordinary course of business and not to influence control of Codexis.
Signatures were provided by Major Shareholding Reporting Analyst Jenny Clarke on 30 Jul 2025. No exhibits indicate activist intent, group formation, or additional derivatives. The disclosure primarily informs investors of a new institutional holder exceeding the 5 % threshold, adding visibility to Codexis’ shareholder base without signaling governance changes.